Gilead Sciences, Inc.

2122 articles about Gilead Sciences, Inc.

• CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)

  5/4/2023

  CHMP Adopts Positive Opinion Recommending Hepcludex ® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV).

• Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

  5/3/2023

  The recent national conversation on hepatitis C (HCV) is an encouraging step towards viral hepatitis elimination in the U.S. With its long history of leadership in viral hepatitis, Gilead continues to support efforts that focus on HCV elimination.

• Gilead Sciences to Present at Upcoming Investor Conferences - May 01, 2023

  5/1/2023

  Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conferences.

• Gilead Sciences Announces First Quarter 2023 Financial Results

  4/27/2023

  Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter of 2023.

• Gilead Sciences Releases Inaugural ESG Impact Report

  4/24/2023

  Gilead Sciences recently released its inaugural Environmental, Social and Governance Impact Report.

• Gilead Sciences: Breaking Down Barriers To Access in HIV and Beyond: A Perspective

  4/19/2023

  When I came to Gilead in 2019, I did so in part because of the revolutionary way this company thinks about bringing therapies to those who could benefit.

• 

  10 Biopharma Companies Hiring AI/ML Talent Now

  4/17/2023

  To help with your job search, here are 10 biopharma companies hiring for Artificial Intelligence and Machine Learning (AI/ML) roles now.

• Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations

  4/16/2023

  Gilead Sciences, Inc. announced positive results from several COVID-19 clinical and real-world evidence studies being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases.

• Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023

  4/13/2023

  Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2023 financial results will be released on Thursday, April 27, 2023 after the market closes.

• Gilead Sciences: 4 Questions: Global Experts Convene To Identify Key Measures to Long-Term Success in HIV

  4/12/2023

  Gilead Sciences: Originally published by Gilead Sciences. Dr. Jeffrey Lazarus was studying at New York University in the late 1980s when he saw first-hand the devastation of the HIV epidemic.

• Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves

  3/27/2023

  Everest Medicines announced that it has received full upfront payment of $280 million from Immunomedics, Inc., a wholly-owned subsidiary of Gilead Sciences, Inc., for the transaction around Trodelvy® rights in certain Asia territories.

• Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement

  3/23/2023

  Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body’s anti-tumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, announced that Pionyr and Gilead Sciences, Inc. have mutually agreed to change their 2020 exclusive option agreements.

• 

  Gilead’s Yescarta Bests Long-Time Standard of Care in R/R LBCL Overall Survival

  3/22/2023

  Yescarta is the first treatment in nearly 30 years to improve overall survival in relapsed/refractory large B-cell lymphoma R/R LBCL, according to Gilead's Kite Pharma.

• Groups Around the World Work to Eliminate Hepatitis C by Meeting People Where They Are

  3/22/2023

  Every Friday for more than two years, a community church in North Wales, U.K., would transform into a one-stop shop of social services for people experiencing homelessness.

• Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities

  3/22/2023

  Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $3 million in grant funding to eight organizations to provide services to communities disproportionately impacted by HIV in rural areas in the United States.

• Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 - March 20, 2023

  3/20/2023

  Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. today announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX‑0479.

• Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479

  3/20/2023

  Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX-0479.

• Public Advisory - Two lots of cystic fibrosis drug Cayston recalled due to the potential of cracked glass vials

  3/18/2023

  Health Canada is advising the public that Gilead Sciences Incorporated recalled two lots of the cystic fibrosis drug Cayston on March 1, 2023, due to the potential of cracked glass vials in those lots, which may introduce glass particles into the medication.

• Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV

  2/22/2023

  Gilead Sciences, Inc. (Nasdaq: GILD) today announced data evaluating lenacapavir in combination with broadly neutralizing antibodies (bNAbs) teropavimab and zinlirvimab as a potential long-acting treatment regimen with twice-yearly dosing.

• Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients

  2/21/2023

  Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive data from three retrospective real-world studies which demonstrated that initiation of Veklury® (remdesivir) within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity.